Brain Tumor Clinical Trials
Brain tumor clinical trials are designed to identify treatments that are potentially more effective and/or have fewer side effects than standard brain tumor treatments. Clinical trials are recommended for patients with tumors where results of treatment are generally poor, or that are considered incurable with conventional treatment. Clinical trials also are recommended for most pediatric patients with brain tumors.
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center patients have access to numerous brain tumor clinical trials, some designed by Cleveland Clinic physicians, others as a part of multi-center trials in partnership with pharmaceutical companies or research consortia. The Burkhardt Brain Tumor Center actively participates in several of these clinical trial groups, including:
- American Brain Tumor Consortium(ABTC)
- Southwest Oncology Group (SWOG)
- Radiation Therapy Oncology Group (RTOG)
- American College of Surgeons Oncology Group (AcoSOG)
- Children's Oncology Group (COG)
These associations contribute to the exciting environment of clinical trial research and development, discussion and the sharing of data that is so important to the dynamic evolution of the therapeutic protocols of tomorrow's brain tumor treatments.
To schedule an evaluation with a Burkhardt Brain Tumor Center specialist, please contact us locally at 216.636.5860 or toll-free at 866.588.2264.
Clinical Trials
Clinical trials (or research studies) help us create the medicine of tomorrow. They provide hope through offering testing of new drugs, new surgical techniques or other treatments before they are widely available.
We can help you access hundreds of clinical trials across all specialty areas. Our new searchable online trials tool makes identifying treatment opportunities easier than ever.
Current Open Protocols & IRB Studies For Treating Brain Tumors
Anaplastic astrocytoma
Newly Diagnosed
- Phase I XL765 + Temodar for Malignant Gliomas IRB CC879
- PARP-1 Inhibitor for Malignant Glioma CC578 NABTT 0703
- Sodium Stibogluconate IRB 7059
Recurrent
Anaplastic oligodendroglioma
Newly Diagnosed
Recurrent
Anaplastic oligodendroglioma, mixed
Newly Diagnosed
Recurrent
Oligoastrocytoma, mixed
Newly Diagnosed
Recurrent
Glioblastoma Multiforme (GBM)
Newly Diagnosed
- Temodar & ABT-888 CC669/NABTT 0801
- Vorinostat, Temodar & RT for Newly Diagnosed GBM CC827/ABTC 0902
- Temozolomide +/- NovoTTF-100A for Newly Diagnosed GBM CC931/NOVO 1308
- Phase I XL765 + Temodar for Malignant Gliomas IRB CC879
- PARP-1 Inhibitor for Malignant Glioma CC578 NABTT 0703
Recurrent
- Tocagen 511 in Recurrent GBM CC949 TOG 1309 - Read more about this trial from the Cleveland Plain Dealer
- Cediranib/Cilengitide for Recurrent GBM CC828/ABTC 0903
- R04929097 for Recurrent/Progressive GBM IRB CC1009 ABTC 0906
- IMC-3G3 or IMC-1121B in Patients with Recurrent GBM IRB CC877
- Stereotactic Radiosurgery Plus Bevacizumab IRB CC845
- Sodium Stibogluconate IRB 7059
Gliosarcoma
Newly Diagnosed
Recurrent
Metastases
- Breast Metastases (DOD) - IRB CC385 CASE 4107
- Sunitinib After SRS for ND Brain Metastases - IRB CC603 CASE 1308